Proliferation rate and breast cancer subtype, but not ALDH1 expression, predict pathological response to neoadjuvant chemotherapy in locally advanced breast cancer

详细信息    查看全文

• 作者：Debajyoti Chatterjee ; Amanjit Bal ; Ashim Das ; Gurpreet Singh
• 关键词：Breast cancer ; Neoadjuvant chemotherapy ; Pathological response ; ALDH1
• 刊名：Virchows Archiv
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：467
• 期：3
• 页码：303-310
• 全文大小：1,139 KB
• 参考文献：1.Cance WG, Carey LA, Calvo BF et al (2002) Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg 236(3):295鈥?02PubMed Central CrossRef PubMed
  2.Ogston KN, Miller ID, Payne S et al (2003) A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12(5):320鈥?CrossRef PubMed
  3.Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z (1995) Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180(3):297鈥?06PubMed
  4.Corben AD, Abi-Raad R, Popa I et al (2013) Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison between classifications and their practical application. Arch Pathol Lab Med 137(8):1074鈥?2CrossRef PubMed
  5.Symmans WF, Peintinger F, Hatzis C et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25(28):4414鈥?2CrossRef PubMed
  6.Chollet P, Abrial C, Durando X et al (2008) A new prognostic classification after primary chemotherapy for breast cancer: residual disease in breast and nodes (RDBN). Cancer J 14(2):128鈥?2CrossRef PubMed
  7.Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26(5):778鈥?5CrossRef PubMed
  8.Khoury T, Ademuyiwa FO, Chandrasekhar R et al (2012) Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy. Mod Pathol 25(3):388鈥?7PubMed Central CrossRef PubMed
  9.Zhong Y, Lin Y, Shen S et al (2013) Expression of ALDH1 in breast invasive ductal carcinoma: an independent predictor of early tumor relapse. Cancer Cell Int 13(1):60PubMed Central CrossRef PubMed
  10.MD Anderson Residual Cancer Burden Calculator. http://鈥媤ww3mdanderson.鈥媜rg/鈥媋pp/鈥媘edcalc/鈥媔ndex.鈥媍fm?鈥媝agename=鈥媕sconvert3 . Published 2007
  11.Wolff AC, Hammond ME, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997鈥?013CrossRef PubMed
  12.Alamgeer M, Ganju V, Kumar B et al (2014) Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Res 16(2):R44PubMed Central CrossRef PubMed
  13.Sahoo S, Lester SC (2009) Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. Arch Pathol Lab Med 133(4):633鈥?2PubMed
  14.Arens N, Bleyl U, Hildenbrand R (2005) HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Arch 446(5):489鈥?6CrossRef PubMed
  15.Tacca O, Penault-Llorca F, Abrial C et al (2007) Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist 12(6):636鈥?3CrossRef PubMed
  16.Pu RT, Schott AF, Sturtz DE, Griffith KA, Kleer CG (2005) Pathologic features of breast cancer associated with complete response to neoadjuvant chemotherapy: importance of tumor necrosis. Am J Surg Pathol 29(3):354鈥?CrossRef PubMed
  17.Patel T, Gupta A, Shah M (2013) Pathological predictive factors for tumor response in locally advanced breast carcinomas treated with anthracyclin-based neoadjuvant chemotherapy. J Cancer Res Ther 9(2):245鈥?CrossRef PubMed
  18.Darb-Esfahani S, Loibl S, Muller BM et al (2009) Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res 11(5):R69PubMed Central CrossRef PubMed
  19.Lips EH, Mulder L, de Ronde JJ et al (2013) Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat 140(1):63鈥?1PubMed Central CrossRef PubMed
  20.Zhang G, Xie W, Liu Z et al (2014) Prognostic function of Ki-67 for pathological complete response rate of neoadjuvant chemotherapy in triple-negative breast cancer. Tumori 100(2):136鈥?2PubMed
  21.Kim KI, Lee KH, Kim TR, Chun YS, Lee TH, Park HK (2014) Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer 17(1):40鈥?PubMed Central CrossRef PubMed
  22.Kang EJ, Jung H, Woo OH et al (2014) Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer. Neoplasma 61(3):352鈥?2CrossRef PubMed
  23.Li H, Ma F, Wang H et al (2013) Stem cell marker aldehyde dehydrogenase 1 (ALDH1)-expressing cells are enriched in triple-negative breast cancer. Int J Biol Markers 28(4):e357鈥?4CrossRef PubMed
  24.Ginestier C, Hur MH, Charafe-Jauffret E et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555鈥?7PubMed Central CrossRef PubMed
  25.Kim YS, Jung MJ, Ryu DW, Lee CH (2014) Clinicopathologic characteristics of breast cancer stem cells identified on the basis of aldehyde dehydrogenase 1 expression. J Breast Cancer 17(2):121鈥?PubMed Central CrossRef PubMed
  26.Gong Y, Wang J, Huo L, Wei W, Ueno NT, Woodward WA (2014) Aldehyde dehydrogenase 1 expression in inflammatory breast cancer as measured by immunohistochemical staining. Clin Breast Cancer 14(3):e81鈥?CrossRef PubMed
  27.Schwartz T, Stark A, Pang J et al (2013) Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women. Cancer 119(3):488鈥?4CrossRef PubMed
  28.Mieog JS, de Kruijf EM, Bastiaannet E et al (2012) Age determines the prognostic role of the cancer stem cell marker aldehyde dehydrogenase-1 in breast cancer. BMC Cancer 12:42PubMed Central CrossRef PubMed
  29.Tanei T, Morimoto K, Shimazu K et al (2009) Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 15(12):4234鈥?1CrossRef PubMed
  30.Lee HE, Kim JH, Kim YJ et al (2011) An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer 104(11):1730鈥?PubMed Central CrossRef PubMed
  
• 作者单位：Debajyoti Chatterjee (1)
  Amanjit Bal (1)
  Ashim Das (1)
  Gurpreet Singh (2)
  
  1. Department of Histopathology, Post Graduate Institute of Medical Education & Research, (PGIMER), Sector鈥?2, Chandigarh, 160012, India
  2. Department of General Surgery, Post Graduate Institute of Medical Education & Research, (PGIMER), Sector鈥?2, Chandigarh, 160012, India
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Pathology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-2307

文摘

For locally advanced breast cancer, pathological complete response (pCR) following neoadjuvant chemotherapy (NACT) is associated with good disease-free survival. In several studies, response to chemotherapy according to various parameters has shown strong inter-individual variability. We investigated whether different prognostic factors, including ALDH1 expression, might predict response to NACT in female patients with locally advanced breast carcinoma. ER, PR, Her2/neu, Ki-67 and ALDH1 immunohistochemistry were performed on the initial biopsy and subsequent resection specimens. Residual tumour burden was calculated in post NACT resection specimens using residual cancer burden (RCB) protocol. Of our cohort of 66 patients, 24 (36 %) achieved pCR. Triple negative phenotype and high Ki-67 proliferative index (>40 %) were significantly associated with good response to NACT. ALDH1 expression in tumour epithelial (20 %) or stromal (44 %) cells did not correlate with tumour grade, molecular subtype, proliferative index or NACT response. However, epithelial and stromal ALDH1 expression was significantly increased in residual tumour after NACT. In conclusion, triple negative phenotype and high proliferative index, but not ALDH1 expression, are predictive of good pathological response to NACT. Increased ALDH1 expression following NACT might be associated with a higher probability of recurrent disease. Keywords Breast cancer Neoadjuvant chemotherapy Pathological response ALDH1